Literatura académica sobre el tema "Pro-hemostatic agents"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Índice
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Pro-hemostatic agents".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Pro-hemostatic agents"
Laurenti, Juliana Bergamasco, Gabriel Zazeri, Ana Paula Ribeiro Povinelli, Moacir Fernandes de Godoy, Domingo Marcolino Braile, Tânia R. Flores da Rocha, Élbio Antônio D' Amico y José Geraldo Nery. "Enhanced pro-coagulant hemostatic agents based on nanometric zeolites". Microporous and Mesoporous Materials 239 (febrero de 2017): 263–71. http://dx.doi.org/10.1016/j.micromeso.2016.10.020.
Texto completoBudko, Elena V., Daria A. Chernikova, Leonid M. Yampolsky y Valentina Y. Yatsyuk. "Local hemostatic agents and ways of their improvement". I.P. Pavlov Russian Medical Biological Herald 27, n.º 2 (2 de julio de 2019): 274–85. http://dx.doi.org/10.23888/pavlovj2019272274-285.
Texto completoOtrocka-Domagała, I., P. Jastrzębski, Z. Adamiak, K. Paździor-Czapula, M. Gesek, M. Mikiewicz y T. Rotkiewicz. "Safety of the long-term application of QuikClot Combat Gauze, ChitoGauze PRO and Celox Gauze in a femoral artery injury model in swine – a preliminary study". Polish Journal of Veterinary Sciences 19, n.º 2 (1 de junio de 2016): 337–43. http://dx.doi.org/10.1515/pjvs-2016-0041.
Texto completoSchoenwaelder, Simone M., Kate E. Jarman, Elizabeth E. Gardiner, My Hua, Jianlin Qiao, Michael J. White, Emma C. Josefsson et al. "Bcl-xL–inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets". Blood 118, n.º 6 (11 de agosto de 2011): 1663–74. http://dx.doi.org/10.1182/blood-2011-04-347849.
Texto completoAgraharkar, M. y M. A. Martinez. "Spontaneous Re-Canalization of Thrombosed Polytetrafluoroethylene (PTFE) Grafts". Journal of Vascular Access 2, n.º 3 (julio de 2001): 114–18. http://dx.doi.org/10.1177/112972980100200306.
Texto completoSivakumar, Walavan, Jian Guan, Jean-Philippe Langevin, Neil A. Martin, Garni Barkhoudarian, Daniel F. Kelly, John Franklin Berry y Aditya K. Iyer. "873 Code Brain Ultra-Early Clinical Pathway for Patient Identification and Management in Spontaneous Non-traumatic Intracranial Hemorrhage Single-Institution Study". Neurosurgery 70, Supplement_1 (abril de 2024): 173. http://dx.doi.org/10.1227/neu.0000000000002809_873.
Texto completoThalji, Nabil K., Lacramioara Ivanciu, Reema Jasuja, Sunita Patel-Hett, Joachim Fruebis, Debra Pittman y Rodney M. Camire. "Zymogen-like FXa Is a Potent Bypassing Agent for Reversal of Direct FXa Inhibitors in Vivo". Blood 124, n.º 21 (6 de diciembre de 2014): 582. http://dx.doi.org/10.1182/blood.v124.21.582.582.
Texto completoElbaz, Carolyne, Katerina Pavenski, Hina Chaudhry, Jerome M. Teitel y Michelle Sholzberg. "The Frequency and Effect of Baseline Cross-Reacting and De Novo Inhibitors to Recombinant Porcine FVIII in Patients with Congenital and Acquired Hemophilia a". Blood 134, Supplement_1 (13 de noviembre de 2019): 1128. http://dx.doi.org/10.1182/blood-2019-122260.
Texto completoHartmann, Rudolf, Tjerk Feenstra, Sabine Knappe, Michael Dockal y Friedrich Scheiflinger. "Elucidating the Excessive Pro-Coagulant Effect of a Sequence Identical Analogue to ACE910 in Combination with Bypassing Agents". Blood 130, Suppl_1 (7 de diciembre de 2017): 90. http://dx.doi.org/10.1182/blood.v130.suppl_1.90.90.
Texto completoJubelirer, Steven J. "Venous Thromboembolism and Malignant Brain Tumors: A Review". Clinical and Applied Thrombosis/Hemostasis 2, n.º 2 (abril de 1996): 130–36. http://dx.doi.org/10.1177/107602969600200208.
Texto completoTesis sobre el tema "Pro-hemostatic agents"
Potzeha, Fanny. "Le potentiel thérapeutique des vésicules extracellulaires hémostatiques pour le traitement ciblé des hémorragies intracérébrales : de la production à grande échelle aux tests dans des modèles pré-cliniques". Electronic Thesis or Diss., Normandie, 2021. http://www.theses.fr/2021NORMC422.
Texto completoIntracerebral hemorrhage (ICH) is the most severe stroke subtype. Stopping the ongoingbleeding using pro-hemostatic agents is a promising therapeutic strategy that remains limitedby serious side effects such as uncontrolled thrombosis. In the present study, we developed anoriginal therapeutic strategy for ICH based on the administration of nanosized extracellularvesicles (EVs) that can trigger the coagulation cascade specifically at the site of active bleeding.We first generated large amounts of EVs from TNF-stimulated THP-1 monocytes in bioreactors.Those monocyte-EVs presented a mean size of around 300 nm, a high pro-hemostatic activityreducing the clotting time in a dose- and TF-dependent manner and a high expression of atargeting protein on their surface (P-Selectin Glycoprotein Ligand 1, PSGL-1). In preclinicalmodels of ICH in mice, intravenous injection of mEVs improved stroke outcome in a dosedependentmanner. mEVs at 1 mg/kg prevented hematoma growth by 43% and improvedneurological score at 24h compared to control mice (p<0.01, n=15/group). These effects werealso present in more severe models of ICH (enoxaparin or warfarin treated mice). Importantly,the beneficial effect was blocked when using antibodies blocking either TF or PSGL-1,suggesting that both the pro-coagulant activity and the ability to target damaged brain vesselsare mandatory for the therapeutic efficacy of EVs. To conclude, exogenous mEVs bearing TFand PSGL-1 improve outcome after collagenase-induced ICH by acting as intravascularhemostatic patches